PortalPublikationenAllogeneic transplantation versus chemotherapy as postremiss...

Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis

Standard

Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. / Stelljes, Matthias; Krug, Utz; Beelen, Dietrich W; Braess, Jan; Sauerland, Maria C; Heinecke, Achim; Ligges, Sandra; Sauer, Tim; Tschanter, Petra; Thoennissen, Gabriela B; Berning, Björna; Kolb, Hans J; Reichle, Albrecht; Holler, Ernst; Schwerdtfeger, Rainer; Arnold, Renate; Scheid, Christoph; Müller-Tidow, Carsten; Woermann, Bernhard J; Hiddemann, Wolfgang; Berdel, Wolfgang E; Büchner, Thomas.

in: J CLIN ONCOL, Jahrgang 32, Nr. 4, 01.02.2014, S. 288-96.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stelljes, M, Krug, U, Beelen, DW, Braess, J, Sauerland, MC, Heinecke, A, Ligges, S, Sauer, T, Tschanter, P, Thoennissen, GB, Berning, B, Kolb, HJ, Reichle, A, Holler, E, Schwerdtfeger, R, Arnold, R, Scheid, C, Müller-Tidow, C, Woermann, BJ, Hiddemann, W, Berdel, WE & Büchner, T 2014, 'Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis', J CLIN ONCOL, Jg. 32, Nr. 4, S. 288-96. https://doi.org/10.1200/JCO.2013.50.5768

APA

Stelljes, M., Krug, U., Beelen, D. W., Braess, J., Sauerland, M. C., Heinecke, A., Ligges, S., Sauer, T., Tschanter, P., Thoennissen, G. B., Berning, B., Kolb, H. J., Reichle, A., Holler, E., Schwerdtfeger, R., Arnold, R., Scheid, C., Müller-Tidow, C., Woermann, B. J., ... Büchner, T. (2014). Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J CLIN ONCOL, 32(4), 288-96. https://doi.org/10.1200/JCO.2013.50.5768

Vancouver

Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J CLIN ONCOL. 2014 Feb 1;32(4):288-96. https://doi.org/10.1200/JCO.2013.50.5768

Bibtex

@article{af4b4bb2d4944e26930db8cd91517f97,
title = "Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis",
abstract = "PURPOSE: The majority of patients with acute myeloid leukemia (AML) who achieve complete remission (CR) relapse with conventional postremission chemotherapy. Allogeneic stem-cell transplantation (alloSCT) might improve survival at the expense of increased toxicity. It remains unknown for which patients alloSCT is preferable.PATIENTS AND METHODS: We compared the outcome of 185 matched pairs of a large multicenter clinical trial (AMLCG99). Patients younger than 60 years who underwent alloSCT in first remission (CR1) were matched to patients who received conventional postremission therapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time in first CR.RESULTS: In the overall pairwise compared AML population, the projected 7-year overall survival (OS) rate was 58% for the alloSCT and 46% for the conventional postremission treatment group (P = .037; log-rank test). Relapse-free survival (RFS) was 52% in the alloSCT group compared with 33% in the control group (P < .001). OS was significantly better for alloSCT in patient subgroups with nonfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, postremission therapy was an independent factor for OS (hazard ratio, 0.66; 95% CI, 0.49 to 0.89 for alloSCT v conventional chemotherapy), among age, cytogenetics, and bone marrow blasts after the first induction cycle.CONCLUSION: AlloSCT is the most potent postremission therapy for AML and is particularly active for patients 45 to 59 years of age and/or those with high-risk cytogenetics.",
keywords = "Adolescent, Adult, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Female, Hematopoietic Stem Cell Transplantation, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute, Male, Matched-Pair Analysis, Middle Aged, Prospective Studies, Remission Induction, Transplantation, Homologous, Treatment Outcome",
author = "Matthias Stelljes and Utz Krug and Beelen, {Dietrich W} and Jan Braess and Sauerland, {Maria C} and Achim Heinecke and Sandra Ligges and Tim Sauer and Petra Tschanter and Thoennissen, {Gabriela B} and Bj{\"o}rna Berning and Kolb, {Hans J} and Albrecht Reichle and Ernst Holler and Rainer Schwerdtfeger and Renate Arnold and Christoph Scheid and Carsten M{\"u}ller-Tidow and Woermann, {Bernhard J} and Wolfgang Hiddemann and Berdel, {Wolfgang E} and Thomas B{\"u}chner",
year = "2014",
month = feb,
day = "1",
doi = "10.1200/JCO.2013.50.5768",
language = "English",
volume = "32",
pages = "288--96",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

RIS

TY - JOUR

T1 - Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis

AU - Stelljes, Matthias

AU - Krug, Utz

AU - Beelen, Dietrich W

AU - Braess, Jan

AU - Sauerland, Maria C

AU - Heinecke, Achim

AU - Ligges, Sandra

AU - Sauer, Tim

AU - Tschanter, Petra

AU - Thoennissen, Gabriela B

AU - Berning, Björna

AU - Kolb, Hans J

AU - Reichle, Albrecht

AU - Holler, Ernst

AU - Schwerdtfeger, Rainer

AU - Arnold, Renate

AU - Scheid, Christoph

AU - Müller-Tidow, Carsten

AU - Woermann, Bernhard J

AU - Hiddemann, Wolfgang

AU - Berdel, Wolfgang E

AU - Büchner, Thomas

PY - 2014/2/1

Y1 - 2014/2/1

N2 - PURPOSE: The majority of patients with acute myeloid leukemia (AML) who achieve complete remission (CR) relapse with conventional postremission chemotherapy. Allogeneic stem-cell transplantation (alloSCT) might improve survival at the expense of increased toxicity. It remains unknown for which patients alloSCT is preferable.PATIENTS AND METHODS: We compared the outcome of 185 matched pairs of a large multicenter clinical trial (AMLCG99). Patients younger than 60 years who underwent alloSCT in first remission (CR1) were matched to patients who received conventional postremission therapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time in first CR.RESULTS: In the overall pairwise compared AML population, the projected 7-year overall survival (OS) rate was 58% for the alloSCT and 46% for the conventional postremission treatment group (P = .037; log-rank test). Relapse-free survival (RFS) was 52% in the alloSCT group compared with 33% in the control group (P < .001). OS was significantly better for alloSCT in patient subgroups with nonfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, postremission therapy was an independent factor for OS (hazard ratio, 0.66; 95% CI, 0.49 to 0.89 for alloSCT v conventional chemotherapy), among age, cytogenetics, and bone marrow blasts after the first induction cycle.CONCLUSION: AlloSCT is the most potent postremission therapy for AML and is particularly active for patients 45 to 59 years of age and/or those with high-risk cytogenetics.

AB - PURPOSE: The majority of patients with acute myeloid leukemia (AML) who achieve complete remission (CR) relapse with conventional postremission chemotherapy. Allogeneic stem-cell transplantation (alloSCT) might improve survival at the expense of increased toxicity. It remains unknown for which patients alloSCT is preferable.PATIENTS AND METHODS: We compared the outcome of 185 matched pairs of a large multicenter clinical trial (AMLCG99). Patients younger than 60 years who underwent alloSCT in first remission (CR1) were matched to patients who received conventional postremission therapy. The main matching criteria were AML type, cytogenetic risk group, patient age, and time in first CR.RESULTS: In the overall pairwise compared AML population, the projected 7-year overall survival (OS) rate was 58% for the alloSCT and 46% for the conventional postremission treatment group (P = .037; log-rank test). Relapse-free survival (RFS) was 52% in the alloSCT group compared with 33% in the control group (P < .001). OS was significantly better for alloSCT in patient subgroups with nonfavorable chromosomal aberrations, patients older than 45 years, and patients with secondary AML or high-risk myelodysplastic syndrome. For the entire patient cohort, postremission therapy was an independent factor for OS (hazard ratio, 0.66; 95% CI, 0.49 to 0.89 for alloSCT v conventional chemotherapy), among age, cytogenetics, and bone marrow blasts after the first induction cycle.CONCLUSION: AlloSCT is the most potent postremission therapy for AML and is particularly active for patients 45 to 59 years of age and/or those with high-risk cytogenetics.

KW - Adolescent

KW - Adult

KW - Age Factors

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Kaplan-Meier Estimate

KW - Leukemia, Myeloid, Acute

KW - Male

KW - Matched-Pair Analysis

KW - Middle Aged

KW - Prospective Studies

KW - Remission Induction

KW - Transplantation, Homologous

KW - Treatment Outcome

U2 - 10.1200/JCO.2013.50.5768

DO - 10.1200/JCO.2013.50.5768

M3 - SCORING: Journal article

C2 - 24366930

VL - 32

SP - 288

EP - 296

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 4

ER -